Pharnext is a France-based clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of neurodegenerative diseases.
Business Model:
Revenue: $90.6k
Employees: 51-200
Address: 46 Rue Saint-Lazare
City: Paris
State: île-de-france
Zip: 75009
Country: FR
Pharnext is a France-based clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of neurodegenerative diseases.
Contact Phone:
Contact Email:
Listed Exchange:
PA
IPO Date:
7/29/2016
Ticker Symbol:
ALPHA
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2021 | Post-IPO Equity | $98.7M | 1/2019 | Post-IPO Equity | $17.1M | 2/2012 | Venture Round | 2 | $10.6M |
Truffle Capital Parinvest Truffle Capital Parinvest |
6/2021 | Convertible Note | $98.7M | 2/2021 | Post-IPO Debt | $6M | 6/2010 | Series A | $0 |
Financière Boscary Truffle Capital Agrinvest Financière Boscary Truffle Capital Agrinvest |
2/2021 | Post-IPO Equity | $7.2M | 3/2020 | Post-IPO Equity | $8.7M | 6/2022 | Post-IPO Debt | $12.8M | 1/2019 | Private Placement | $17M | 3/2020 | Private Placement | $8.6M | 9/2011 | Series B | 2 | $3.5M |
Parinvest Truffle Capital Truffle Capital Parinvest Truffle Capital Truffle Capital |
4/2018 | Private Placement | $19.7M | 8/2022 | Post-IPO Debt | $2.5M |
Néovacs |
6/2010 | Series A | 3 | $5.8M |
Financière Boscary Truffle Capital Aurinvest Financière Boscary Truffle Capital Aurinvest |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|